Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 40% ± 25% |
Insufficient scRNA-seq data for expression of HABP2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 14693.14 | 226 / 226 | 95% | 226.83 | 384 / 406 |
pancreas | 100% | 911.42 | 328 / 328 | 74% | 26.82 | 132 / 178 |
kidney | 99% | 1433.26 | 88 / 89 | 53% | 44.65 | 481 / 901 |
stomach | 79% | 344.38 | 285 / 359 | 41% | 14.23 | 117 / 286 |
lung | 51% | 19.17 | 293 / 578 | 35% | 11.95 | 403 / 1155 |
muscle | 85% | 39.00 | 681 / 803 | 0% | 0 | 0 / 0 |
heart | 79% | 36.85 | 684 / 861 | 0% | 0 | 0 / 0 |
prostate | 48% | 10.06 | 117 / 245 | 4% | 0.41 | 20 / 502 |
blood vessel | 44% | 5.81 | 582 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 9% | 3.24 | 130 / 1445 | 31% | 10.22 | 57 / 183 |
uterus | 29% | 16.72 | 50 / 170 | 10% | 3.40 | 45 / 459 |
intestine | 14% | 2.81 | 136 / 966 | 23% | 6.50 | 120 / 527 |
brain | 33% | 12.83 | 884 / 2642 | 2% | 0.13 | 15 / 705 |
breast | 29% | 7.65 | 135 / 459 | 5% | 0.62 | 54 / 1118 |
ovary | 13% | 5.53 | 24 / 180 | 3% | 0.32 | 11 / 430 |
peripheral blood | 15% | 9.24 | 138 / 929 | 0% | 0 | 0 / 0 |
adipose | 11% | 3.92 | 131 / 1204 | 0% | 0 | 0 / 0 |
spleen | 7% | 19.07 | 18 / 241 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 7% | 1.26 | 35 / 504 |
thymus | 6% | 0.75 | 37 / 653 | 1% | 0.05 | 4 / 605 |
skin | 4% | 0.88 | 73 / 1809 | 0% | 0.02 | 2 / 472 |
adrenal gland | 4% | 0.69 | 11 / 258 | 0% | 0 | 0 / 230 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007155 | Biological process | cell adhesion |
GO_0006508 | Biological process | proteolysis |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0008233 | Molecular function | peptidase activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
GO_0005539 | Molecular function | glycosaminoglycan binding |
Gene name | HABP2 |
Protein name | Hyaluronan-binding protein 2 (EC 3.4.21.-) (Factor VII-activating protease) (Factor seven-activating protease) (FSAP) (Hepatocyte growth factor activator-like protein) (Plasma hyaluronan-binding protein) [Cleaved into: Hyaluronan-binding protein 2 50 kDa heavy chain; Hyaluronan-binding protein 2 50 kDa heavy chain alternate form; Hyaluronan-binding protein 2 27 kDa light chain; Hyaluronan-binding protein 2 27 kDa light chain alternate form] Brevican core protein |
Synonyms | HGFAL PHBP |
Description | FUNCTION: Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly. It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form. Activates coagulation factor VII . May function as a tumor suppressor negatively regulating cell proliferation and cell migration . . |
Accessions | ENST00000351270.4 [Q14520-1] Q14520 Q8IWX2 ENST00000542051.5 [Q14520-2] |